ClinicalTrials.gg
RecruitingNCT07039253ETHR2Updated Jun 4, 2026

Pilot Trial of Clinic-based Dating Violence Prevention Program for Adolescents and Caregivers

An interventional study of Engaging Together for Health Relationships in Dating Violence, Parent and Primary Care, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

ETHR V 2.0 pilot trial is a one-arm, multi-site pilot trial to assess the acceptability and feasibility of Engaging Together for Healthy Relationships, a caregiver-adolescent dating violence prevention program delivered within pediatric primary care.

Read the detailed description

ETHR V 2.0 pilot trial is a one-arm (intervention only) pilot trial of Engaging Together for Healthy Relationships, a caregiver-adolescent dating violence prevention program delivered within pediatric primary care. We completed one round of the pilot trial in two clinics in Pittsburgh and now are expanding the trial to include two sites with all providers in each site. ETHR includes clinician training, in-clinic resources, and after visit text messages and resources for families. This is an intervention only trial to assess acceptability, feasibility, and exploratory pre/post changes in outcomes.

02

Conditions studied

  • Dating Violence
  • Parent
  • Primary Care

Browse trials for

Keywords

  • dating violence prevention
  • parental monitoring and communication
  • pilot trial
  • middle school
03

In context

Communication

719 studies on the registry are indexed under Communication; 159 are open to participants now.

This study's planned enrollment of 120 is below the median of 144 across 571 interventional studies indexed under Communication.

Browse Communication studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,419 studies on the registry; 168 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers:

  1. Sees patient at an eligible primary care clinic
  2. Speaks and understands English
  3. Age 18 or older
  4. Identifies as a pediatrician, nurse practitioner, physician assistant (pediatric primary care healthcare provider)

Adolescents

  1. Age 12 to 16
  2. Attending an upcoming well-child visit from a provider enrolled in the study
  3. Caregiver who is accompanying well-child visit with adolescent is also participating
  4. Speaks and understands English

Parents

  1. Is parent or primary caregiver for an adolescent age 12 to 16
  2. Adolescent has an upcoming well-child visit with a provider enrolled in the study
  3. Accompanying child to the well-visit
  4. Adolescent is interested and eligible to participate in study
  5. Speaks and understand English

Exclusion criteria

Exclusion Criteria:

  • Unable to assent/consent
  • Does not meet inclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Engaging Together for Healthy Relationships

    Providers and families in the intervention arm will receive the ETHR program which includes a clinician training, provider scripts, resource guides, a take home box for families, post-visit text messages, a comprehensive website, and warm referral processes.

    Behavioral: Engaging Together for Health Relationships

Interventions

  • BehavioralEngaging Together for Health Relationships

    Dating violence intervention for caregivers and adolescents to be delivered within pediatric primary care

06

What researchers measure

Primary outcomes

  1. Percentage of participants who are eligible out of the total who are approached

    Will assess through tracking data

    Time frame: Through completion of study recruitment, an average of 6 months

  2. Percentage of participants who are consented out of the total who are eligible

    Will assess through tracking data

    Time frame: Through completion of study recruitment, an average of 6 months

  3. Percentage of participants who complete the baseline survey out of the total who consented

    Will assess through tracking data

    Time frame: Through completion of completing baseline surveys, an average of 6 months

  4. Percentage of participants who complete the well-visit out of the total who consented

    Will assess through tracking data

    Time frame: Through completion of completing well-visits, an average of 6 months

  5. Percentage of participants who complete the immediate post-intervention survey out of the total who consented

    Will assess through tracking data

    Time frame: Through completion of completing post-intervention survey, an average of 7 months

  6. Percentage of participants who complete the 1-month post-intervention survey out of the total who consented

    Through completion of completing 1- month post-intervention survey, an average of 8 months

    Time frame: 4 months

  7. Percentage of participants who complete the 3-month post-intervention survey out of the total who consented

    Will assess through tracking data

    Time frame: Through completion of completing 3 month post-intervention survey, an average of 12 months

  8. Percentage of participants who strongly agree or agree that the intervention is acceptable using a 4-item validated measure (Acceptability of Intervention Measure)

    Validated measure (Acceptability of Intervention Measure)

    Time frame: Through completion of completing immediate post-visit surveys, an average of 6 months

  9. Percent of participants who received intervention during pediatric primary care visit

    Investigator-developed measure with questions about what components of the intervention were received during the well visit

    Time frame: Through completion of completing well-visits, an average of 6 months

  10. Participants use intervention resources after the visit

    Investigator-developed measure on use of intervention resources after the visit

    Time frame: Through completion of intervention, on average 3 months post well visit

Secondary outcomes

  1. Self-efficacy in preventing adolescent relationship abuse (ARA), change in outcome between baseline and 3 months

    Self-efficacy around ARA prevention, 1-5 scale (5=higher self-efficacy)

    Time frame: Baseline, 3-month post intervention

  2. Percentage of participants who utilize ARA resources at each measurement point, change in outcome over time

    Investigator developed measure (yes/no)

    Time frame: Baseline, 1 month post intervention, 3 month post-intervention

  3. Attitudes about ARA, change in outcome between baseline and 3 months

    Attitudes about Abusive Relationships, 1-5 scale (1=not abusive, 5=very abusive)

    Time frame: Baseline, 3-month post intervention

  4. Motivation around preventing dating violence

    Investigator developed measure, 1-5 scale (1=not motivated, 5=very motivated)

    Time frame: Baseline, 3-month post intervention

  5. Parent-adolescent communication around dating and ARA, change in outcome over time

    Investigator developed measure, yes/no answer choices (yes=has communicated, no=has not communicated)

    Time frame: Baseline, 3-month post intervention

  6. Parental monitoring around dating and ARA, change in outcome over time

    Investigator developed measure, 1-5 scale (1=never; 5=always)

    Time frame: Baseline, 3-month post intervention

  7. Percentage of adolescents reporting ARA victimization and perpetration

    CADRI Short Form 1-5 scale (never to everyday)

    Time frame: Baseline, 3-month post intervention

  8. ARA knowledge

    3 questions assessing ARA knowledge (yes/no answer choices)

    Time frame: baseline, 3 months surveys (6 months total)

07

Study locations

1 of 1 sites recruiting
  • UPMC Children's Community Practice
    Monongahela, Pennsylvania 15063, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — To protect confidentiality and due to the sensitivity of this topic, we will not share IDP

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07039253
Responsible party
Maya Ragavan (Assistant Professor, University of Pittsburgh) — Principal investigator
First posted
Jun 26, 2025
Start date
Aug 15, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Erin Mickievicz, BA
Contact
mickieviczee@upmc.edu
14126926000
Maya Ragavan
Contact
ragavanm@chp.edu
4126926000
Maya Ragavan, MD, MPH, MS
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion